THE COVID-19 DRUG FROM SOUTH KOREA INTRODUCED IN WORLD CLASS ACADEMIC JOURNAL

Highlights: 

• CNPharm, the major shareholder in Hyundai Bioscience, has published an article regarding research results of CP-COV03, an oral treatment for COVID-19.
• Hyundai Biosciences is all set to start the first trials in Korea and internationally after positive preclinical studies of CNPharm. 
• CNPharm has developed the antiviral drug by improving the bioavailability of Niclo....
  Click here to read more

  ---

  Tags : COVID-19, academic, journal, drug, healthcare,

  ---

  SHARE THIS ARTICLE